Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs. In Vivo Bedinvetmab (0.5-1 mg/kg; s.c. for 28 d) alleviates the pain associated with canine osteoarthritis . Bedinvetmab (1 mg/kg; s.c. monthly; 3× and 10× dose multiples) is well tolerated in normal laboratory Beagle dogs for 6 months and with 2 weeks' concurrent NSAID administration. MCE has not independently confirmed the accuracy of these methods. They are for reference only.